Relmada Therapeutics Future Growth

Future criteria checks 0/6

Relmada Therapeutics is forecast to grow earnings and revenue by 3% and 60.5% per annum respectively while EPS is expected to grow by 21.1% per annum.

Key information

3.0%

Earnings growth rate

21.1%

EPS growth rate

Pharmaceuticals earnings growth	22.9%
Revenue growth rate	60.5%
Future return on equity	n/a
Analyst coverage	Low
Last updated	10 Apr 2024

Recent future growth updates

Recent updates

Relmada Therapeutics: Run Up Into Results May Resume Following This Drop

Mar 21

Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

Mar 13

Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark

Jan 14

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Dec 04

Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure

Oct 14

Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up

Sep 14

Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression

Aug 09

We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely

Jul 14

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Feb 26

4 Clinical Catalysts On Tap For Relmada In 2022

Jan 28

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

Nov 04

Our First Look At Relmada Therapeutics

Jun 28

We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Jun 28

Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

Mar 09

What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?

Jan 15

Enrollment underway in Relmada Therapeutics' late-stage depression study with REL-1017

Dec 07

Relmada Therapeutics (RLMD) Investor Presentation - Slideshow

Dec 02

Relmada Therapeutics (RLMD) Investor Presentation - Slideshow

Nov 16

Earnings and Revenue Growth Forecasts

NasdaqGS:RLMD - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	31	-170	N/A	N/A	3
12/31/2025	3	-120	N/A	N/A	5
12/31/2024	N/A	-112	N/A	N/A	5
12/31/2023	N/A	-99	-52	-52	N/A
9/30/2023	N/A	-112	-77	-77	N/A
6/30/2023	N/A	-129	-93	-93	N/A
3/31/2023	N/A	-144	-101	-101	N/A
12/31/2022	N/A	-157	-104	-104	N/A
9/30/2022	N/A	-153	-106	-106	N/A
6/30/2022	N/A	-157	-100	-100	N/A
3/31/2022	N/A	-143	-95	-95	N/A
12/31/2021	N/A	-126	-92	-92	N/A
9/30/2021	N/A	-112	-61	-61	N/A
6/30/2021	N/A	-86	-53	-53	N/A
3/31/2021	N/A	-71	-40	-40	N/A
12/31/2020	N/A	-59	-28	-28	N/A
9/30/2020	N/A	-43	-25	-25	N/A
6/30/2020	N/A	-30	-15	-15	N/A
3/31/2020	N/A	-23	-14	-14	N/A
12/31/2019	N/A	-15	-12	-12	N/A
9/30/2019	N/A	-18	-11	-11	N/A
6/30/2019	N/A	-17	-10	-10	N/A
3/31/2019	N/A	-17	-9	-9	N/A
12/31/2018	N/A	-17	-9	-9	N/A
9/30/2018	N/A	-11	-7	-7	N/A
6/30/2018	N/A	-9	-6	-6	N/A
3/31/2018	N/A	-7	-5	-5	N/A
12/31/2017	N/A	-6	-5	-5	N/A
9/30/2017	N/A	-6	N/A	-5	N/A
6/30/2017	N/A	-6	N/A	-6	N/A
3/31/2017	N/A	-8	N/A	-8	N/A
12/31/2016	N/A	-8	N/A	-10	N/A
9/30/2016	N/A	-9	N/A	-12	N/A
6/30/2016	N/A	-3	N/A	-13	N/A
3/31/2016	N/A	6	N/A	-15	N/A
12/31/2015	N/A	6	N/A	-16	N/A
9/30/2015	N/A	14	N/A	-17	N/A
6/30/2015	N/A	-21	N/A	-16	N/A
3/31/2015	N/A	-55	N/A	-13	N/A
12/31/2014	N/A	-46	N/A	-9	N/A
9/30/2014	N/A	-56	N/A	-5	N/A
6/30/2014	N/A	-28	N/A	-3	N/A
3/31/2014	N/A	-13	N/A	-3	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RLMD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RLMD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RLMD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RLMD is forecast to have no revenue next year.

High Growth Revenue: RLMD is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RLMD's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Relmada Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased by 24% to US$12.83

Price target increased by 19% to US$12.67

Price target decreased to US$17.42

Price target decreased to US$17.42

Price target increased to US$66.00

Price target decreased to US$65.86

Recent updates

Relmada Therapeutics, Inc., Annual General Meeting, May 24, 2024

Relmada Therapeutics: Run Up Into Results May Resume Following This Drop

Relmada Therapeutics, Inc. to Report Fiscal Year 2023 Results on Mar 19, 2024

Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

New major risk - Share price stability

CEO & Director recently bought US$387k worth of stock

Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Price target increased by 24% to US$12.83

Relmada Therapeutics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Relmada Therapeutics to Present New Preclinical Data on Its Psilocybin Program At AASLD the Liver Meeting 2023

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

Relmada Therapeutics, Inc. Announces Dosing of First Patient in Relight, a Phase 3 Trial of Relight, a Phase 3 Trial of Relight for the Adjunctive Treatment of Major Depressive Disorder

Price target increased by 19% to US$12.67

New major risk - Revenue and earnings growth

Relmada Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell Small Cap Comp Value Index

Relmada Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Relmada Therapeutics, Inc. Appoints Fabiana Fedeli to Board of Directors

Relmada Therapeutics, Inc. Appoints Cedric O'Gorman MD as Chief Medical Officer

We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

CEO & Director recently bought US$116k worth of stock

Relmada Therapeutics, Inc. Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder

Price target decreased to US$17.42

High number of new and inexperienced directors

Price target decreased to US$17.42

Relmada Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure

Relmada Therapeutics Inc. Announces Top-line Results from Phase 3 RELIANCE III Trial for REL 1017 as a Monotherapy for the Treatment of Major Depressive Disorder

Price target increased to US$66.00

Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 Reliance III Trial for REL-1017 as A Monotherapy for Major Depressive Disorder

Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up

Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression

Relmada Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Relmada Therapeutics, Inc. Appoints John Hixon as Head of Commercial

We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely

CEO & Director exercised options and sold US$83k worth of stock

Relmada Therapeutics, Inc. Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology

High number of new and inexperienced directors

Relmada Therapeutics, Inc., Annual General Meeting, May 25, 2022

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 VS Ketamine for Abuse Potential

4 Clinical Catalysts On Tap For Relmada In 2022

Relmada Therapeutics, Inc. Announces Publication of Rel-1017 Phase 2 Study Results in the American Journal of Psychiatry

Price target decreased to US$65.86

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

Independent Chairman of the Board notifies of intention to sell stock

Price target increased to US$70.80

Independent Chairman of the Board notifies of intention to sell stock

Our First Look At Relmada Therapeutics

We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Independent Chairman of the Board notifies of intention to sell stock

Price target increased to US$69.50

Independent Chairman of the Board notifies of intention to sell stock

Relmada Therapeutics, Inc. Announces Poster Presentation at the American Society for Pharmacology and Experimental Therapeutics Annual Meeting at Experimental Biology 2021

Independent Chairman of the Board notifies of intention to sell stock

Relmada Therapeutics, Inc. to Report Q4, 2020 Results on Mar 23, 2021

Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

CEO & Director exercised options and sold US$310k worth of stock

CEO & Director notifies of intention to sell stock

What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?

New 90-day high: US$39.28

Independent Chairman of the Board notifies of intention to sell stock

Relmada Therapeutics, Inc. Announces Resignation of Thomas Wessel as Executive Vice President and Head of Research and Development

Relmada Therapeutics, Inc. Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder

Enrollment underway in Relmada Therapeutics' late-stage depression study with REL-1017

Independent Chairman of the Board notifies of intention to sell stock